<p>Polaryx Therapeutics Inc. announced the selection of a contract research organization (CRO) for its SOTERIA Phase 2 basket trial. The trial will evaluate the safety, tolerability, and clinical activity of the company’s lead candidate, PLX-200, across four lysosomal storage disorders. The trial is expected to begin in the first half of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9655595-en) on February 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

PLYX

<p>Polaryx Therapeutics Inc. has selected a contract research organization (CRO) for its SOTERIA Phase 2 trial, which will assess the safety, tolerability, and clinical activity of its lead candidate, PLX-200, in four lysosomal storage disorders. The trial is set to commence in the first half of 2026.</p>

Polaryx Therapeutics selects CRO for SOTERIA Phase 2 trial